176 related articles for article (PubMed ID: 13129812)
1. LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress.
Schoepp DD; Wright RA; Levine LR; Gaydos B; Potter WZ
Stress; 2003 Sep; 6(3):189-97. PubMed ID: 13129812
[TBL] [Abstract][Full Text] [Related]
2. Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice.
Linden AM; Shannon H; Baez M; Yu JL; Koester A; Schoepp DD
Psychopharmacology (Berl); 2005 Apr; 179(1):284-91. PubMed ID: 15619115
[TBL] [Abstract][Full Text] [Related]
3. Anxiolytic activity of the MGLU2/3 receptor agonist LY354740 on the elevated plus maze is associated with the suppression of stress-induced c-Fos in the hippocampus and increases in c-Fos induction in several other stress-sensitive brain regions.
Linden AM; Greene SJ; Bergeron M; Schoepp DD
Neuropsychopharmacology; 2004 Mar; 29(3):502-13. PubMed ID: 14694349
[TBL] [Abstract][Full Text] [Related]
4. The anxiolytic action of mGlu2/3 receptor agonist, LY354740, in the fear-potentiated startle model in rats is mechanistically distinct from diazepam.
Tizzano JP; Griffey KI; Schoepp DD
Pharmacol Biochem Behav; 2002 Sep; 73(2):367-74. PubMed ID: 12117591
[TBL] [Abstract][Full Text] [Related]
5. Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors.
Helton DR; Tizzano JP; Monn JA; Schoepp DD; Kallman MJ
J Pharmacol Exp Ther; 1998 Feb; 284(2):651-60. PubMed ID: 9454811
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).
Rorick-Kehn LM; Johnson BG; Burkey JL; Wright RA; Calligaro DO; Marek GJ; Nisenbaum ES; Catlow JT; Kingston AE; Giera DD; Herin MF; Monn JA; McKinzie DL; Schoepp DD
J Pharmacol Exp Ther; 2007 Apr; 321(1):308-17. PubMed ID: 17204749
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors.
Monn JA; Valli MJ; Massey SM; Hansen MM; Kress TJ; Wepsiec JP; Harkness AR; Grutsch JL; Wright RA; Johnson BG; Andis SL; Kingston A; Tomlinson R; Lewis R; Griffey KR; Tizzano JP; Schoepp DD
J Med Chem; 1999 Mar; 42(6):1027-40. PubMed ID: 10090786
[TBL] [Abstract][Full Text] [Related]
8. Comparison of c-Fos induction in the brain by the mGlu2/3 receptor antagonist LY341495 and agonist LY354740: evidence for widespread endogenous tone at brain mGlu2/3 receptors in vivo.
Linden AM; Bergeron M; Schoepp DD
Neuropharmacology; 2005; 49 Suppl 1():120-34. PubMed ID: 16023151
[TBL] [Abstract][Full Text] [Related]
9. Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344.
Rorick-Kehn LM; Perkins EJ; Knitowski KM; Hart JC; Johnson BG; Schoepp DD; McKinzie DL
J Pharmacol Exp Ther; 2006 Feb; 316(2):905-13. PubMed ID: 16223873
[TBL] [Abstract][Full Text] [Related]
10. Effects of mGlu2 or mGlu3 receptor deletions on mGlu2/3 receptor agonist (LY354740)-induced brain c-Fos expression: specific roles for mGlu2 in the amygdala and subcortical nuclei, and mGlu3 in the hippocampus.
Linden AM; Baez M; Bergeron M; Schoepp DD
Neuropharmacology; 2006 Aug; 51(2):213-28. PubMed ID: 16733060
[TBL] [Abstract][Full Text] [Related]
11. LY354740, a potent group II metabotropic glutamate receptor agonist prevents lactate-induced panic-like response in panic-prone rats.
Shekhar A; Keim SR
Neuropharmacology; 2000 Apr; 39(7):1139-46. PubMed ID: 10760357
[TBL] [Abstract][Full Text] [Related]
12. Metabotropic glutamate II receptor agonists in panic disorder: a double blind clinical trial with LY354740.
Bergink V; Westenberg HG
Int Clin Psychopharmacol; 2005 Nov; 20(6):291-3. PubMed ID: 16192835
[TBL] [Abstract][Full Text] [Related]
13. The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats.
Cartmell J; Monn JA; Schoepp DD
J Pharmacol Exp Ther; 1999 Oct; 291(1):161-70. PubMed ID: 10490900
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder.
Dunayevich E; Erickson J; Levine L; Landbloom R; Schoepp DD; Tollefson GD
Neuropsychopharmacology; 2008 Jun; 33(7):1603-10. PubMed ID: 17712352
[TBL] [Abstract][Full Text] [Related]
15. Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans.
Grillon C; Cordova J; Levine LR; Morgan CA
Psychopharmacology (Berl); 2003 Aug; 168(4):446-54. PubMed ID: 12709777
[TBL] [Abstract][Full Text] [Related]
16. Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia?
DD DD; Marek GJ
Curr Drug Targets CNS Neurol Disord; 2002 Apr; 1(2):215-25. PubMed ID: 12769628
[TBL] [Abstract][Full Text] [Related]
17. Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex.
Marek GJ; Wright RA; Schoepp DD; Monn JA; Aghajanian GK
J Pharmacol Exp Ther; 2000 Jan; 292(1):76-87. PubMed ID: 10604933
[TBL] [Abstract][Full Text] [Related]
18. Distribution and abundance of metabotropic glutamate receptor subtype 2 in rat brain revealed by [3H]LY354740 binding in vitro and quantitative radioautography: correlation with the sites of synthesis, expression, and agonist stimulation of [35S]GTPgammas binding.
Richards G; Messer J; Malherbe P; Pink R; Brockhaus M; Stadler H; Wichmann J; Schaffhauser H; Mutel V
J Comp Neurol; 2005 Jun; 487(1):15-27. PubMed ID: 15861463
[TBL] [Abstract][Full Text] [Related]
19. LY354740: a metabotropic glutamate receptor agonist which ameliorates symptoms of nicotine withdrawal in rats.
Helton DR; Tizzano JP; Monn JA; Schoepp DD; Kallman MJ
Neuropharmacology; 1997; 36(11-12):1511-6. PubMed ID: 9517421
[TBL] [Abstract][Full Text] [Related]
20. Effects of a metabotropic glutamate(2/3) receptor agonist (LY544344/LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: preliminary results.
Kellner M; Muhtz C; Stark K; Yassouridis A; Arlt J; Wiedemann K
Psychopharmacology (Berl); 2005 Apr; 179(1):310-5. PubMed ID: 15821951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
